Vaccine production not perfect but our drug saves lives, AstraZeneca says, as Africa backs COVID-19 shot

(Correcting to show CEO was referring to vaccine production not efficacy in headline, first and 4th paragraphs) By Pushkala Aripaka and Ludwig Burger (Reuters) - The production of AstraZeneca's COVID-19 vaccine has not been perfect but the shot will have a big impact on the pandemic, its chief executive said on Thursday, as the drugmaker pledged to double output by April and the African Union gave its backing for the shot. The two-dose inoculation, developed with Oxford University, has been hailed as a 'vaccine for the world' because it is cheaper and easier to distribute than some rivals. But its rapid approval in Europe and elsewhere has been clouded by doubts over its most effective dosage and interval between doses.

Reuters February 13, 2021 00:06:44 IST
Vaccine production not perfect but our drug saves lives, AstraZeneca says, as Africa backs COVID-19 shot

Vaccine production not perfect but our drug saves lives AstraZeneca says as Africa backs COVID19 shot

(Correcting to show CEO was referring to vaccine production not efficacy in headline, first and 4th paragraphs)

By Pushkala Aripaka and Ludwig Burger

(Reuters) - The production of AstraZeneca's COVID-19 vaccine has not been perfect but the shot will have a big impact on the pandemic, its chief executive said on Thursday, as the drugmaker pledged to double output by April and the African Union gave its backing for the shot.

The two-dose inoculation, developed with Oxford University, has been hailed as a "vaccine for the world" because it is cheaper and easier to distribute than some rivals.

But its rapid approval in Europe and elsewhere has been clouded by doubts over its most effective dosage and interval between doses.

Data at the weekend also showed it was less effective against a fast-spreading variant of the virus in South Africa, prompting the country to pause rollout of the shot. The company has also been embroiled in a row with the European Union over supply delays but Soriot said AstraZeneca was working to ramp up output as fast as possible.

"Is it perfect? No, it's not perfect, but it's great. Who else is making 100 million doses in February?" CEO Pascal Soriot said on a conference call about the vaccine.

"We're going to save thousands of lives and that's why we come to work everyday."

The company said it aimed to produce more than 200 million doses per month by April, double this month's level as the world tries to tame a pandemic that has killed 2.35 million.

Head of operations Pam Cheng said on the call that the group was working to further expand global capacity and productivity.

AstraZeneca has set a target to produce 3 billion doses this year, with India's Serum Institute making much of that aimed at poorer nations.

On Wednesday, the company enlisted Germany's IDT Biologika as a contract manufacturer, but the bulk of IDT's contribution will only come onstream late next year.

AstraZeneca said it expected much-anticipated data from the U.S. trial of the vaccine before the end of March, and that it was confident the shot offered relatively good protection against severe disease and death for the South African variant. Its disappointing results were against milder cases.

However, after rising to become Britain's most valuable company last summer, the company has now slipped to sixth, in a move some analysts attribute to doubts over the vaccine.

"In a year or two we will look back and everybody will realise we made a big impact," Soriot said.

POSTER CHILD

AstraZeneca's shares were up 0.95% in afternoon trade, paring some earlier gains, after the company forecast a pick up in earnings growth this year on strong demand for its cancer and other new therapies.

It has pledged not to make any money from its COVID-19 vaccine during the pandemic.

It has been a tumultuous week for the drugmaker after South Africa put on hold giving the shot to its citizens, choosing one developed by its U.S. rival Johnson & Johnson instead.

That came after the trial data raised concerns about the AstraZeneca vaccine's effectiveness on mild symptoms from the more infectious 501Y.V2 variant of the virus dominant in South Africa, which has spread to 41 nations around the world.

Despite that blow, the World Health Organization endorsed the British vaccine on Wednesday and the African Union said it would target its use in countries that have not reported cases of the variant.

Kenya and Morocco are also planning to administer it.

AstraZeneca said it expected 2021 revenues to rise by a low teens percentage and core earnings of $4.75 to $5.00 per share, as it beat expectations for fourth-quarter sales.

The earnings guidance equates to 18-24% growth, after 15% in 2020, but was a little lower than the $5.10 per share analysts were expecting, as the company flagged more spending this year.

The COVID-19 vaccine is not included in the guidance and the company said its sales would be reported separately from the first quarter of 2021.

While public interest is focused on the vaccine, AstraZeneca's core business of diabetes, heart, kidney, and cancer medicines has been steadily growing, helping the company to turn around years of decline.

"The company is arguably the poster child for big pharma turnarounds," said Third Bridge senior analyst Sebastian Skeet.

(Reporting by Pushkala Aripaka and Ludwige Burger. Editing by Josephine Mason and Jon Boyle)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

also read

France, Germany to agree to NATO role against Islamic State - sources
| Reuters
World

France, Germany to agree to NATO role against Islamic State - sources | Reuters

By Robin Emmott and John Irish | BRUSSELS/PARIS BRUSSELS/PARIS France and Germany will agree to a U.S. plan for NATO to take a bigger role in the fight against Islamic militants at a meeting with President Donald Trump on Thursday, but insist the move is purely symbolic, four senior European diplomats said.The decision to allow the North Atlantic Treaty Organization to join the coalition against Islamic State in Syria and Iraq follows weeks of pressure on the two allies, who are wary of NATO confronting Russia in Syria and of alienating Arab countries who see NATO as pushing a pro-Western agenda."NATO as an institution will join the coalition," said one senior diplomat involved in the discussions. "The question is whether this just a symbolic gesture to the United States

China's Xi says navy should become world class
| Reuters
World

China's Xi says navy should become world class | Reuters

BEIJING Chinese President Xi Jinping on Wednesday called for greater efforts to make the country's navy a world class one, strong in operations on, below and above the surface, as it steps up its ability to project power far from its shores.China's navy has taken an increasingly prominent role in recent months, with a rising star admiral taking command, its first aircraft carrier sailing around self-ruled Taiwan and a new aircraft carrier launched last month.With President Donald Trump promising a US shipbuilding spree and unnerving Beijing with his unpredictable approach on hot button issues including Taiwan and the South and East China Seas, China is pushing to narrow the gap with the U.S. Navy.Inspecting navy headquarters, Xi said the navy should "aim for the top ranks in the world", the Defence Ministry said in a statement about his visit."Building a strong and modern navy is an important mark of a top ranking global military," the ministry paraphrased Xi as saying.